AstraZeneca reported a 20% increase in cancer drug sales.
The company faced setbacks or 'pipeline blips' in its drug development efforts.
This news is highlighted in recent pharmaceutical industry reporting as of early 2026.
AstraZeneca reported a 20% increase in cancer drug sales.
The company faced setbacks or 'pipeline blips' in its drug development efforts.
This news is highlighted in recent pharmaceutical industry reporting as of early 2026.